Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.3%

5 terminated/withdrawn out of 54 trials

Success Rate

89.8%

+3.3% vs industry average

Late-Stage Pipeline

11%

6 trials in Phase 3/4

Results Transparency

32%

14 of 44 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 1

39(72.2%)

Phase 2

9(16.7%)

Phase 3

4(7.4%)

Phase 4

2(3.7%)

54Total

Phase 1(39)

Phase 2(9)

Phase 3(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials

NCT03491683Phase 1Active Not Recruiting

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Role: lead

NCT03603808Phase 2Completed

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Role: collaborator

NCT04398433Phase 1Completed

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Role: lead

NCT02772003Phase 1Active Not Recruiting

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Role: collaborator

NCT04367675Phase 1Active Not Recruiting

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Role: collaborator

NCT04588428Phase 2Completed

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Role: lead

NCT05293249Phase 1Completed

dMAbs for Prevention of COVID-19

Role: collaborator

NCT05781542Phase 1Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Role: collaborator

NCT03502785Phase 1Completed

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Role: lead

NCT02809443Phase 1Completed

GLS-5700 in Dengue Virus-Naïve Adults

Role: collaborator

NCT03721978Phase 3Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Role: lead

NCT03835533Phase 1Completed

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Role: collaborator

NCT04642638Phase 2Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Role: lead

NCT03831503Phase 1Completed

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Role: collaborator

NCT03180684Phase 2Completed

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Role: lead

NCT03185013Phase 3Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Role: lead

NCT03499795Phase 2Completed

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Role: lead

NCT03606213Phase 1Completed

Therapeutic Vaccination in Treated HIV Disease

Role: collaborator

NCT04093076Phase 1Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Role: lead

NCT05430958Phase 1Withdrawn

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Role: lead